Three medical ventures, including Quratis, move into Osong Cheombok Complex in Cheongju.


Three health and medical venture companies, including Quratis, a developer of tuberculosis prevention vaccines, will build production lines and research facilities at the Osong-chopdan Medical Complex in Cheongju, North Chungcheong Province.

The cities of North Chungcheong Province and Cheongju reached investment agreements worth a total of 68.3 billion won with three health and medical companies -- Quratis, Autotelic Korea and Actsvision -- at the North Chungcheong Provincial Government on Wednesday.

From this year to 2021, these companies will relocate their headquarters, factories and research institutes to or from the Osong Chumbok Complex.

Quratis, a strategic partnership with the U.S.-based IDRI, is leading the domestication of anti-tuberculosis vaccines for adults and will establish a GMP plant, headquarters and research center to manufacture vaccines in the Osong-Attack Complex.

Autotelic Korea is a company that has the technology to manufacture TDM devices and has entered the U.S. market with a new improved drug and is also developing a combination of diabetes and high blood pressure.

Acts Vision, a leading company in the one-time endoscopy field, holds 12 related patents. The company has unique technical skills in the field of optical fiber technology-based endoscopes that are easy to insert, the province explained.

"If Quratis and three other companies move into Osong, the Osong Chumbok complex will pave the way for the fourth industrial revolution," a provincial government official said. "We will actively seek to attract promising bio companies from now on."